StOIC-1: Study of Opioid-Induced Constipation 1 Project

Sponsor
Royal Surrey County Hospital NHS Foundation Trust (Other)
Overall Status
Completed
CT.gov ID
NCT04350112
Collaborator
Kyowa Hakko Kirin UK, Ltd. (Industry)
1,007
16
24.3
62.9
2.6

Study Details

Study Description

Brief Summary

The aim of the project is to investigate opioid-induced constipation (OIC) in a real world / diverse group of patients with cancer.

The objectives of the project are to determine: a) prevalence of OIC; b) clinical features / impact of OIC; c) management of OIC.

Condition or Disease Intervention/Treatment Phase
  • Other: Clinical assessment

Detailed Description

StOIC-1 is an observational study, and will involve a single visit (see below for schedule).

The following data will be collected: a) demographic data - age, gender, ethnicity; b) cancer diagnosis; c) opioid medications - drug, formulation, dose; d) laxative medications - drug, formulation, dose; e) other medications; f) Eastern Co-operative Oncology Group performance status

The participants will be asked the following questions:
  1. Simple question - "Are you constipated?" [Options - yes / no / unsure]

  2. European Association for Palliative Care definition question - "Does the following question describe your bowel function: 'the passage of small, hard faeces infrequently and with difficulty?' [Options - yes / no / unsure]

  3. Camilleri definition question - "Does the following statement describe your bowel function: 'a change since initiating opioid therapy from baseline bowel habits that is characterised by any of the following: reduced bowel movement frequency, development or worsening of straining to pass bowel movements, a sense of incomplete rectal evacuation, harder stool consistency?' [Options - yes / no / unsure

  4. Rome IV diagnostic criteria for OIC

The participants will also be asked to complete:
  1. Bowel function index (BFI). The BFI is a validated, 3 item, patient-reported tool for assessing the treatment of OIC. A BFI score of ≥30 indicates suboptimally treated OIC.

  2. Patient Assessment of Constipation - Quality of Life Questionnaire (PAC-QOL). The PAC-QOL is a validated, 28-item, patient-reported tool for assessing the impact of constipation over time.

  3. Memorial Symptom Assessment Scale - Short Form (MSAS-SF). The MSAS-SF is a validated, 32 item, patient-reported tool for assessing physical and psychological symptoms in cancer patients.

The participant will also undergo a palliative care specialist assessment for constipation / OIC. The palliative care specialist will be asked to review the patient with regard to their bowel function, and then asked the following questions: a) does the patient have constipation? [Options - yes / no / unsure]; b) (if appropriate) does the patient have opioid-induced constipation? [Options - yes / no / unsure]; c) (if appropriate) does the patient have additional causes of constipation? [Options - yes / no / unsure]; d) (if appropriate) what additional causes of constipation?I

Study Design

Study Type:
Observational
Actual Enrollment :
1007 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
An Observational Study of Diagnostic Criteria, Clinical Features and Management of Opioid-induced Constipation (OIC) in Patients With Cancer Pain
Actual Study Start Date :
Aug 21, 2017
Actual Primary Completion Date :
Aug 30, 2019
Actual Study Completion Date :
Aug 30, 2019

Outcome Measures

Primary Outcome Measures

  1. Prevalence of opioid-induced constipation [1 week]

    Clinician assessment

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 18yr; diagnosis of cancer; diagnosis of cancer pain; receipt of regular opioids for at least one week
Exclusion Criteria:
  • Inability to give informed consent; inability to complete questionnaire

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal Cornwall Hospital Truro Cornwall United Kingdom TR1 3LQ
2 Brighton & Sussex University Hospitals Brighton East Sussex United Kingdom BN2 5BE
3 Leckhampton Court Hospice Cheltenham Gloucestershire United Kingdom GL53 0QJ
4 Hospice of St. Francis Berkhamstead Hertfordshire United Kingdom HP43GW
5 Heart of Kent Hospice Maidstone Kent United Kingdom ME20 7PU
6 Wisdom Hospice Rochester Kent United Kingdom ME1 2NU
7 St. Raphael's Hospice Cheam London United Kingdom SM3 9DX
8 Nottingham University Hospitals Nottingham Nottinghamshire United Kingdom
9 St Margaret's Hospice Yeovil Somerset United Kingdom BA20 2HU
10 St. Giles Hospice Lichfield Staffordshire United Kingdom WS14 9LH
11 Royal Surrey County Hospital Guildford Surrey United Kingdom GU2 7XX
12 Birmingham St. Mary's Hospice Birmingham West Midlands United Kingdom B29 7DA
13 St. Catherine's Hospice Crawley West Sussex United Kingdom RH10 6BH
14 St. Gemma's Hospice Leeds Yorkshire United Kingdom LS17 6QD
15 Wheatfields Hospice Leeds Yorkshire United Kingdom LS6 2AE
16 St. Luke's Hospice Sheffield Yorkshire United Kingdom S11 9NE

Sponsors and Collaborators

  • Royal Surrey County Hospital NHS Foundation Trust
  • Kyowa Hakko Kirin UK, Ltd.

Investigators

  • Principal Investigator: Andrew N Davies, MD, Consultant Palliative Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Royal Surrey County Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT04350112
Other Study ID Numbers:
  • StOIC-1 Project
First Posted:
Apr 16, 2020
Last Update Posted:
Apr 16, 2020
Last Verified:
Apr 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Royal Surrey County Hospital NHS Foundation Trust
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 16, 2020